SRSF11: A Potential Drug Target for Neurodegenerative Disorders

Target Name: SRSF11

NCBI ID: G9295

SRSF11

SRSF11: A Potential Drug Target for Neurodegenerative Disorders

SRSF11 (dJ677H15.2) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the SRSF1 family, which is characterized by the presence of a unique transmembrane domain and a characteristic conserved domain. SRSF11 is unique among its family members due to the presence of a unique N-terminal hypervariable region (HVR) that is highly conserved across its sequence and has been implicated in various cellular processes.

SRSF11 has been identified as a potential drug target due to its involvement in several cellular processes that are crucial for the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. SRSF11 has also been shown to play a role in several diseases, including neuropsychiatric disorders, cancer, and autoimmune diseases.

One of the key functions of SRSF11 is its role in the regulation of cell adhesion and migration. SRSF11 is a critical regulator of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues and is crucial for the development and progression of various diseases.

SRSF11 has been shown to regulate tight junction formation and maintenance through its involvement in several signaling pathways, including the TGF-β pathway and the Focal Adhesion molecule (FAM) pathway. TGF-β is a well-known transcription factor that regulates cell growth, differentiation, and inflammation, while FAM is a protein that plays a role in cell-cell adhesion and has been implicated in various diseases, including cancer.

SRSF11 has also been shown to regulate the migration of cells through the regulation of the activity of several intracellular signaling pathways, including the TGF-β pathway, the FAM pathway, and the Src/FAK signaling pathway. TGF-β and Src are both transcription factors that regulate cell growth, while FAK is a protein that plays a role in cell-cell adhesion and has been implicated in various diseases, including cancer.

In addition to its role in cell adhesion and migration, SRSF11 has also been shown to regulate the formation and maintenance of neurotransmitter receptors. SRSF11 is a critical regulator of the neurotransmitter receptor PSD90, which is involved in the regulation of several neurotransmitter signaling pathways, including the GABAergic neurotransmission pathway.

SRSF11 has also been shown to play a role in the regulation of cellular processes that are crucial for the development and progression of cancer. It has been shown to regulate the migration of cancer cells through the regulation of the activity of several intracellular signaling pathways, including the TGF-β pathway, the FAM pathway, and the Src/FAK signaling pathway.

In conclusion, SRSF11 is a protein that plays a critical role in several cellular processes that are crucial for the development and progression of various diseases. Its unique N-terminal HVR and its involvement in several signaling pathways make it an attractive drug target for the development of new treatments for neurodegenerative disorders, cancer, and autoimmune diseases. Further research is needed to fully understand the role of SRSF11 in these diseases and to develop new treatments that target this protein.

Protein Name: Serine And Arginine Rich Splicing Factor 11

Functions: May function in pre-mRNA splicing

The "SRSF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRSF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets